^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

    Excerpt:
    ...- Histologically or cytologically confirmed diagnosis of advanced or metastatic cutaneous melanoma that is determined to be BRAFV600 wild type and either NRAS wild type or NRAS mutation type....
    Trial ID:
    NCT02065063
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res
    Title:

    An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma

    Excerpt:
    Due to the inability of single agent palbociclib to induce cell death, we explored whether CDK4/6 targeting sensitized melanoma cells to MEK targeting.…The combination of palbociclib and trametinib reduced the viability of BRAF and NRAS mutant cell lines compared to single agent treatments.
    DOI:
    10.1158/0008-5472.CAN-15-3384